microRNAs in the Diagnosis of Atherosclerotic Plaque Instability

Sponsor
I.M. Sechenov First Moscow State Medical University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05680935
Collaborator
(none)
60
1
2
23.9
2.5

Study Details

Study Description

Brief Summary

It's a non-randomized, intervention, prospective, single-center study.

The aim of the work is to identify of biomarkers of unstable atherosclerosis in brachiocephalic arteries

Tasks:
  • identify microRNAs, the expression of which is characteristic of unstable atherosclerotic lesions;

  • to assess the relationship of miRNA and trimethylamine N-oxide with the progression of unstable atherosclerotic lesions;

  • to determine the effect of the level of plasma trimethylamine N-oxide on the progression of atherosclerotic lesions.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: blood microRNA
  • Diagnostic Test: plaque and intima microRNA
  • Diagnostic Test: histological examination of the plaque
  • Diagnostic Test: blood level trimethyl N-oxide
N/A

Detailed Description

The recruitment of patients will be carried out at the University Clinical Hospital No. 1 of Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University). The study will include up to 50 people - the study group with atherosclerosis of the brachiocephalic arteries and up to 30 people - the control group without brachiocephalic atherosclerosis.

As part of the standard of medical care, the patient has already undergone and received the results of the following examinations before being included in the study:

  • general clinical laboratory tests (complete blood count, urinalysis, low density lipoproteins, very low density lipoproteins, high density lipoproteins, total cholesterol, triglycerides, total protein, alanine aminotransferase, aspartate aminotransferase, creatinine, urea, glucose)

  • ultrasound and/or multislice computed tomography (MSCT) of brachiocephalic arteries.

Patients with clinically significant atherosclerosis of the brachiocephalic arteries were hospitalized for an operation - carotid endarterectomy with obtaining surgical material (atherosclerotic plaque with adjacent intima).

Specific methods of the planned study (procedures for examination and treatment of the patient):

  1. In addition, all patients will take blood (20 ml) from the cubital vein to isolate microRNAs and determine the plasma content of trimethylamine N-oxide (TMAO). The resulting surgical material will be sent for histological examination and microRNA isolation.

  2. The following statistical data processing methods will be used: frequency distribution, arithmetic mean, mode, median, standard deviation, determination of normal distribution, Student's t-test, Pearson's test, Fisher's test, Spearman's correlation coefficient, multiple linear regression.

During the operation according to the standard protocol of carotid endarterectomy, an atherosclerotic plaque with a small area of adjacent intima is removed. An atherosclerotic plaque obtained during a carotid endarterectomy will be sent for histological examination to determine signs of instability. The obtained data will be compared with the level of isolated microRNAs in blood and tissue (atherosclerotic plaque, intima) to detect microRNAs, which are determined during an unstable course of the atherosclerotic process.

The data obtained will make it possible to predict the unstable course of atherosclerosis using non-invasive studies. This will allow timely detection of unstable plaques and help to make a decision and determine the tactics of managing patients with borderline sizes of atherosclerotic lesions.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
The Importance of Determining the Expression Level of Various microRNAs in the Diagnosis of Atherosclerotic Plaque Instability
Actual Study Start Date :
Sep 5, 2022
Anticipated Primary Completion Date :
Aug 31, 2024
Anticipated Study Completion Date :
Aug 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: atherosclerosis of the brachiocephalic arteries

The recruitment of patients will be carried out at the University Clinical Hospital No. 1 of the Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University). The study will include up to 50 people - the study group with atherosclerosis of the brachiocephalic arteries.

Diagnostic Test: blood microRNA
all patients will receive blood (20 ml) from the cubital vein for microRNA isolation.

Diagnostic Test: plaque and intima microRNA
The resulting surgical material will be sent for microRNA isolation.

Diagnostic Test: histological examination of the plaque
The resulting surgical material (atherosclerotic plaque) will be sent for histological examination.

Diagnostic Test: blood level trimethyl N-oxide
all patients will receive blood (20 ml) from the cubital vein for determination of plasma trimethyl N-oxide (TMAO) content.

Experimental: No brachiocephalic atherosclerosis

The recruitment of patients will be carried out at the University Clinical Hospital No. 1 of the Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University). Up to 30 people - the control group without brachiocephalic atherosclerosis.

Diagnostic Test: blood microRNA
all patients will receive blood (20 ml) from the cubital vein for microRNA isolation.

Diagnostic Test: blood level trimethyl N-oxide
all patients will receive blood (20 ml) from the cubital vein for determination of plasma trimethyl N-oxide (TMAO) content.

Outcome Measures

Primary Outcome Measures

  1. blood microRNA [at study entry, before carotid endarterectomy.]

    blood sampling from the cubital vein 20.0 ml before surgery centrifuge ethylenediaminetetraacetic acid (EDTA) tubes with blood (ELMI centrifuge, Centrifuge model CM-6M) once at 1000 g for 10 minutes to sediment the cells; select from above ¾ of the plasma volume, so as not to capture cells, into a new empty tube; centrifuge the plasma at 2500 g for 15 minutes to sediment platelets. Remove ¾ of the supernatant without touching the pellet and transfer to a new tube. Repeat the procedure again; Aliquot the supernatant taken a second time into 1.0 ml Eppendorf tubes. Freeze (Thermo Scientific refrigerator-freezer) and store at -70˚C, -80˚C.

  2. plaque microRNA [immediately after carotid endarterectomy]

    - after receiving an atherosclerotic plaque and adjacent intima during the operation of carotid endarterectomy The atherosclerotic plaque obtained during the surgical intervention (carotid endarterectomy) is cut in half, the adjacent part of the intima is cut off. One half of the plaque is placed in a tube with 10% neutral buffered formalin solution and sent for histological examination. The second half and intima are placed in different test tubes with RNAprotect Tissue Reagent (Qiagen), cooled at +2 ˚С +4 ˚С, then frozen (Thermo Scientific refrigerator-freezer) and stored at -70˚С, -80˚С.

  3. blood TMAO [at study entry, before carotid endarterectomy]

    blood sampling from the cubital vein 20.0 ml before surgery centrifuge the ethylenediaminetetraacetic acid (EDTA) tube with blood (ELMI centrifuge, Centrifuge model CM-6M) at 2300 g for 15 minutes; take 1.0 ml from the obtained plasma into 2 Eppendorf tubes; Freeze (Thermo Scientific refrigerator-freezer) and store at -70˚C, -80˚C.

  4. histological examination of atherosclerotic plaque [immediately after carotid endarterectomy]

    - after receiving an atherosclerotic plaque and adjacent intima during the operation of carotid endarterectomy The atherosclerotic plaque obtained during the surgical intervention (carotid endarterectomy) is cut in half, the adjacent part of the intima is cut off. One half of the plaque is placed in a tube with 10% neutral buffered formalin solution and sent for histological examination.

  5. intima microRNA [immediately after carotid endarterectomy]

    after receiving an atherosclerotic plaque and adjacent intima during the operation of carotid endarterectomy the intima obtained during the surgical intervention (carotid endarterectomy) is placed in a tube with RNAprotect Tissue Reagent (Qiagen), cooled at +2 ˚С +4 ˚С, then frozen (Thermo Scientific refrigerator-freezer) and stored at -70˚С, -80˚С.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. Availability of written informed consent to participate in research work;

  2. Age from 18 to 85 years;

  3. Availability of data from a general blood test, blood lipid profile (total cholesterol, very low density lipoproteins, low density lipoproteins, high density lipoproteins, triglycerides);

  4. Absence of clinical signs of atherosclerosis of brachiocephalic arteries (no stroke, transient ischemic attack. On auscultation of the carotid arteries, there are no additional noises);

  5. Absence of signs of atherosclerosis of the brachiocephalic arteries according to ultrasound duplex scanning (USDS) and/or multispiral computed tomography (MSCT) angiography of the brachiocephalic arteries;

  6. Conducted outpatient visit at a research center with clinical and biochemical blood tests performed, ultrasound examination of arterial vessels and/or multispiral tomography of arterial vessels with contrast enhancement and/or hospitalization at a research center.

Non-inclusion criteria:
  1. Chronic kidney disease stage 3b and above (glomerular filtration rate < 45 ml / min / 1.73 sq.m);

  2. The presence of severe somatic pathology (with the exception of atherosclerosis of the carotid arteries and conditions caused by it), reducing life expectancy to less than 6 months;

  3. Chronic somatic diseases in the acute stage;

  4. Weight less than 40kg and more than 125kg;

  5. Pregnancy.

Exclusion Criteria

  1. Refusal to continue participation in the study.

Contacts and Locations

Locations

Site City State Country Postal Code
1 I.M. Sechenov First Moscow State Medical University (Sechenov University) Moscow Russian Federation 119991

Sponsors and Collaborators

  • I.M. Sechenov First Moscow State Medical University

Investigators

  • Principal Investigator: Anastasiia Lomonosova, no, I.M. Sechenov First Moscow State Medical University (Sechenov University)

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
I.M. Sechenov First Moscow State Medical University
ClinicalTrials.gov Identifier:
NCT05680935
Other Study ID Numbers:
  • 132578
First Posted:
Jan 11, 2023
Last Update Posted:
Jan 11, 2023
Last Verified:
Dec 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by I.M. Sechenov First Moscow State Medical University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 11, 2023